FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.

doi:10.1158/1078-0432.CCR-20-0232

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2021

Bernat-Peguera Adrià, Navarro-Ventura Juan, Lorenzo-Sanz Laura, da Silva-Diz Victoria, Bosio Mattia, Palomero Luis, Penin Rosa M, Pérez Sidelnikova Diana, Bermejo Josep Oriol, Taberna Miren, Vilariño Noelia, Piulats Josep M, Mesia Ricard, Viñals Joan Maria, González-Suárez Eva, Capella-Gutierrez Salvador, Villanueva Alberto, Viñals Francesc, Muñoz Purificación

Abstract excerpt

PURPOSE: Recurrent and/or metastatic unresectable cutaneous squamous cell carcinomas (cSCCs) are treated with chemotherapy or radiotherapy, but have poor clinical responses. A limited response (up to 45% of cases) to EGFR-targeted therapies was observed in clinical trials with patients with advanced and metastatic cSCC. Here, we analyze the molecular traits underlying the response to EGFR inhibitors, and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mice, Inbred NOD

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to Gefitinib

Share to Mice, SCID

Share to Neoplasms, Glandular and Epithelial

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Skin Neoplasms

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed

Identifiers

PMID: 33262138
DOI: 10.1158/1078-0432.CCR-20-0232

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma.PMID 33262138Read ↗

FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signalingSemantic proximity Read ↗

FGFR2 in the Development and Progression of Cutaneous Squamous Cell CancerSemantic proximity Read ↗

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.Semantic proximity Read ↗

Establishment and molecular characterization of HCB-541, a novel and aggressive human cutaneous squamous cell carcinoma cell line.Semantic proximity Read ↗

Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograftSemantic proximity Read ↗

Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.Semantic proximity Read ↗

Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLCSemantic proximity Read ↗

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome.Semantic proximity Read ↗

A tEMTing target? - Clinical and Experimental Evidence for Epithelial-Mesenchymal Transition in the Progression of Cutaneous Squamous Cell Carcinoma (A Scoping Systematic Review)Semantic proximity Read ↗

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 ExpressionSemantic proximity Read ↗

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.